Is ALMS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Envudeucitinib psoriasis approval path, with product revenue (ttm) at ~$0 (clinical-stage, no approved products). The bear case rests on as a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. Analysts covering it are spread from $25.00 to $55.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $25.00, -5.2% from the $26.38 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Envudeucitinib psoriasis approval path. The lead asset delivered strong Phase 3 skin-clearance results in plaque psoriasis, and management has guided to an NDA filing in the second half of 2026. The most optimistic analyst target on ALMS is $55.00, +108.5% from the $26.38 price. That figure is only reachable if this thesis works close to its best case.

As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. FDA approval is not guaranteed, and even after approval the TYK2 space is competitive, led by Bristol Myers Squibb's already-marketed Sotyktu (deucravacitinib) and other entrants in development. Future equity raises could dilute existing holders, and integration of the ACELYRIN merger adds execution risk. Any single clinical, safety, or commercial disappointment could move the stock sharply, which is characteristic of pre-revenue biotech. The most pessimistic published target is $25.00, -5.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Alumis Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Envudeucitinib psoriasis approval path) stalling in the reported numbers rather than in the narrative, the risk above (as a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Alumis is a clinical-stage biopharmaceutical company developing oral, precision-designed therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (ESK-001), is an oral TYK2 inhibitor being developed for plaque psoriasis and other autoimmune conditions.

No. As of mid-2026 Alumis is clinical-stage with no FDA-approved products, so it generates essentially no product revenue and funds operations from cash on its balance sheet. Its value rests on the potential of its pipeline rather than current sales.

Envudeucitinib, formerly called ESK-001, is Alumis's lead oral allosteric TYK2 inhibitor. It posted positive Phase 3 ONWARD1 and ONWARD2 results in moderate-to-severe plaque psoriasis (roughly 65% PASI 90 and over 40% PASI 100 at week 24), with an NDA planned for the second half of 2026.